Subcutaneous Histaglobulin as an Emerging Therapy in Refractory Chronic Urticaria: A Clinical Evaluation

Abstract

Background: Chronic urticaria (CU) is a persistent condition characterized by recurrent hives and itching, often resistant to standard treatments. Subcutaneous Histaglobulin, an immunomodulatory agent, has emerged as a potential therapeutic option for refractory CU. This study aims to evaluate the efficacy and safety of SC Histaglobulin in managing patients with refractory chronic urticaria.
Methods: A clinical evaluation was conducted with 50 patients diagnosed with refractory CU. Participants received SC Histaglobulin (2 mL weekly) for 8 weeks. Outcomes were assessed using the Urticaria Activity Score (UAS7), Dermatology Life Quality Index (DLQI), and visual analog scale (VAS) for pruritus. Data were collected at baseline, during treatment, and at 4 weeks post-treatment. Statistical analyses included paired t-tests and Wilcoxon signed-rank tests.
Results: The mean UAS7 score decreased significantly from 31.4 ± 6.2 at baseline to 12.1 ± 5.4 at the end of the treatment (p < 0.001), with 40% of patients achieving complete symptom resolution. DLQI scores improved from 15.8 ± 4.3 to 6.4 ± 3.1 (p < 0.001), and VAS scores for pruritus reduced from 7.6 ± 1.4 to 2.5 ± 1.1 (p < 0.001). SC Histaglobulin was well-tolerated, with mild adverse events reported.
Conclusion: SC Histaglobulin is an effective and well-tolerated treatment for refractory chronic urticaria, significantly improving symptoms and quality of life. The study supports the use of SC Histaglobulin as a viable therapeutic option in this challenging patient population, although further research is needed to confirm these findings and explore long-term outcomes.